44 results about "Serum plasma" patented technology

The invention discloses a preparation method of a CGRP detection kit and application of the CGRP detection kit in migraine diagnosis, and belongs to the technical field of biological medicine detection. According to the invention, alpha-CGRP polypeptide coupled KLH protein is subjected to efficient animal immunization, an antibody with good affinity is screened by using methods such as enzyme-linked immunosorbent assay, cross pairing analysis is carried out, and final antibody sequence information is obtained through sequencing. The paired monoclonal antibody screened by the invention has high sensitivity (KD value of 1nM), the limit of detection (LoD) can be as low as pg / mL level, a low-concentration CGRP sample can be effectively detected, the matrix effect of human serum / plasma can be effectively neutralized by an optimized sample diluent formula, and the repeatability is high (in-plate and inter-plate CV values of 1t and 10%). According to the invention, the kit prepared from the specific paired antibody is systematically and closely linked with the indication function of migraine for the first time, and a clinical diagnosis direction is provided.

The invention discloses a plasma or serum exosome separation method which comprises the following steps: firstly, coupling an antibody for resisting four transmembrane protein CD81 on the surface of an exosome by using a magnetic bead to form an immunomagnetic bead; pretreating a serum / plasma sample, enriching exosomes, co-incubating with the immunomagnetic beads, washing the magnetic beads after incubation capture is completed, and washing off uncombined impurities; after being captured, the exosome can be directly cracked, the magnetic beads are removed for downstream experiments, or the magnetic beads are eluted to obtain the complete exosome. The exosome affinity antibody is matched with the magnetic beads, the plasma / serum sample exosome is separated, the unique affinity separation technology not only can remove high-abundance protein in the serum / plasma sample, but also can eliminate other vesicles with similar membrane structures with the exosome, so that the purity of the separated exosome is far higher than that of the exosome obtained by other separation methods.

The application discloses a red blood cell alloantibody specificity analysis method, and aims at the defects in the prior art that a large amount of manual experience and subjective judgment are relied on to exclude positive antigens according to the results of non-agglutination of samples to be detected and cells, and scientific methods such as statistics are lacked to verify the reliability of detection results, and provides a red blood cell alloantibody specificity analysis method. According to the expression of red blood cell antigens of spectrum cells / anti-screen cells and the agglutination results of patient serum / plasma, the red blood cell alloantibody specificity is analyzed by using programmed analysis logic and statistical result analysis.

The invention belongs to the technical field of biological detection, and particularly relates to a monoclonal antibody combination for NfL protein detection and application. The combination comprises monoclonal antibodies 9E1 and 10B4, and amino acid sequences of complementary determining regions of heavy chain and light chain variable regions of the monoclonal antibodies 9E1 and 10B4 are respectively shown as SEQ ID NO.1-12. The antibody combination can be used for constructing a double-antibody sandwich ELISA detection system and is especially suitable for being combined with a biotin-avidin signal amplification system to achieve high-sensitivity and high-specificity detection of the NfL protein, the detection sensitivity can reach 20 pg / mL, and the method is low in cost, easy and convenient to operate and suitable for quantitative analysis of the NfL protein in samples such as serum and plasma.

The invention relates to in vitro detection of biomarkers associated with drug-induced liver injury; belongs to the technical field of immunokits. The technical scheme provided by the invention is as follows: the soluble myeloid cell triggered receptor-1 is applied to preparation of a product for diagnosing the drug-induced liver injury as a biomarker. The invention discloses and proves that sTREM1 in serum or plasma can be used as a specific biomarker for diagnosing drug-induced liver injury (DILI), especially drug-induced liver fatty degeneration injury for the first time. The serum / plasma sTREM1 can detect abnormal rise in the extremely early stage (such as 7 days after medication) of the drug-induced liver injury, which is about 5-7 days earlier than that of the traditional marker ALT / AST, so that a key early intervention time window is provided for clinicians, and the liver injury can be prevented from further worsening.

The present invention discloses a method for simultaneously detecting a plurality of fat-soluble vitamins and steroid hormones, comprising the following steps: adding an internal standard to a serum sample, mixing, and then adding methyl tert-butyl ether for extraction; extracting the components to be tested into an organic solvent, centrifuging, drying the extract with nitrogen, re-dissolving, and then injecting and analyzing the extract on a liquid chromatography-mass spectrometry system. The detection method of the present invention can simultaneously detect the contents of five fat-soluble vitamins and seventeen steroid hormones in serum (plasma), and simultaneously test a total of 22 substances to be tested, which is accurate and can be quantitatively detected. The present invention adopts a scheme that changes the conventional prior art of using the isotope of the substance to be tested as the internal standard substance, and adopts trenbolone cyclohexylmethyl carbonate as the internal standard, which can simultaneously quantify 22 substances to be tested, greatly reducing the workload.

The invention belongs to the technical field of biology, and discloses a sample diluent for ELISA (Enzyme-Linked Immunosorbent Assay), application of the sample diluent and a kit. The sample diluent comprises the following components: sodium chloride, sodium dodecyl sarcosinate and sodium caseinate, the mass ratio of the sodium chloride to the sodium dodecyl sarcosinate to the sodium caseinate is (1.6-6.4): (0.01-0.1): (0.5-2); according to the sample diluent, the synergistic effect of sodium chloride, sodium dodecyl sarcosinate and sodium caseinate with different concentrations is utilized, and matrix interference in animal serum / plasma can be remarkably reduced, so that the sensitivity and specificity of an ELISA kit are improved.

The invention discloses an erythrocyte isoantibody specificity analysis method, and aims to overcome the defects that in the prior art, when positive antigens are excluded according to non-agglutination results of a sample to be detected and cells, a large amount of artificial experience and subjective judgment are relied on, and scientific methods such as statistics are lacked to verify the credibility of the detection results. The invention provides an erythrocyte isoantibody specificity analysis method. According to erythrocyte antigen expression of spectrum cells / anti-screening cells and patient serum / plasma agglutination results, erythrocyte isoantibody specificity is analyzed by using programmed analysis logic and statistical results.

A method for the extraction and enrichment of Hepatitis C Virus (HCV) antigens by conjugating specific antibodies targeting Envelope 1, Envelope 2, NS3, and NS4 antigens to a temperature-responsive smart polymer (NIPAAm-Co-HIPAAm-Co-SAKIPAAm). The application also relates to a detection kit for HCV antigens, comprising the smart polymer conjugated to specific antibodies, colloidal gold nanoparticles conjugated to specific antibodies, and instructions for detecting HCV antigens in serum, plasma, or whole blood samples.

The application discloses application of a reagent for detecting ILA concentration in preparation of a product for predicting the curative effect of esophageal squamous cell carcinoma immunotherapy, a prediction method and equipment, and relates to the technical field of immunotherapy curative effect prediction. The reagent for detecting indole-3-lactic acid concentration is aimed at samples selected from serum, plasma, blood, tumor tissue or fecal samples. By establishing a prediction model for the curative effect of esophageal squamous cell carcinoma immunotherapy, the curative effect of immunotherapy on esophageal squamous cell carcinoma patients can be accurately predicted, valuable reference bases can be provided for clinicians, thus helping to formulate individualized immunotherapy strategies and improving the curative effect of immunotherapy.

The application provides a detection method of small molecule substances. The detection method comprises the following steps: mixing, incubating and mixing a sample, a diluent and a ligand, the small molecule substances in the sample are specifically combined with the ligand to form an immune complex, a complex antibody labeled with a signal generator is added, the complex antibody is specifically combined with a new conformation formed by the small molecule substances and the ligand to form a ternary immune complex, and the content of the ternary immune complex is detected; the molecular weight of the small molecule substance to be detected is less than 2000D; the diluent comprises a metal chelate and a buffer; the metal chelate comprises EDTA-2K or EDTA-2Na; the sample is a serum sample or a plasma sample, and the method solves the problem of detection difference between serum and plasma blood collection tube samples in the existing small molecule detection field.

The present application relates to the field of rapid diagnostic technology, and more specifically, discloses an antigen detection test strip and a preparation method thereof; the test strip comprises a base plate and a sample pad, a blank pad, a nitrocellulose membrane and a water-absorbing pad sequentially overlapped on the base plate in the chromatography direction; the nitrocellulose membrane is provided with a marking area, a detection line and a quality control line; the marking area, the detection line and the quality control line are sequentially located on the nitrocellulose membrane along the chromatography direction; the detection line is coated with a detection antibody, and the quality control line is coated with a quality control antigen or antibody; an NC membrane treatment component and a quantum dot conjugate are sequentially fixed on the marking area, and the quantum dot conjugate is superimposed on the NC membrane treatment component. The present application can achieve rapid release of the labeled conjugate, and can be detected using a small amount of peripheral blood / venous whole blood / serum / plasma sample, and a report can be issued within 5 minutes. It has the advantages of being easy to use, simple to operate and easy to promote.

The present invention belongs to the field of biological detection technology, and specifically relates to an anti-monkey interleukin-6 monoclonal antibody, an enzyme-linked immunosorbent assay kit and its application. Named IL-6-12, IL-6-12 includes a heavy chain variable region and a light chain variable region; the heavy chain variable region has three complementary determining regions CDR-H1 to CDR-H3, and the amino acid sequence is shown in SEQ ID NO.6-SEQ ID NO.8; the light chain variable region has three complementary determining regions CDR-L1 to CDR-L3, and the amino acid sequence is shown in SEQ ID NO.9-SEQ ID NO.11. The monoclonal antibody of the present invention can specifically bind to monkey interleukin-6, and the above-mentioned monoclonal antibody is used to screen a pairable monoclonal antibody. Based on the combination of the monoclonal antibodies, a monkey interleukin-6 enzyme-linked immunosorbent assay kit is obtained, which can detect the content of monkey interleukin-6 in monkey serum, plasma or tissue fluid.

The utility model provides a reagent card for whole blood separation liquid phase test, which comprises a card body, a separation cavity and an extraction cavity are arranged on the card body, a liquid outlet is arranged at the bottom of the separation cavity, and the liquid outlet is communicated with the extraction cavity; a filter membrane covering the liquid outlet is fixed in the separation cavity; a supercharging device is arranged in the separation cavity and used for increasing the air pressure in the separation cavity. A whole blood separation structure is arranged on the reagent card, when blood plasma or serum needs to be detected, collected whole blood is added into the separation cavity, the pressurizing device increases the air pressure in the separation cavity, the whole blood permeates the filtering membrane under the dual action of gravity and the air pressure to obtain the blood plasma or serum, the blood plasma or serum flows into the extraction cavity through the liquid outlet, and then the blood plasma or serum is extracted. A centrifugal device or a filtering device does not need to be additionally adopted for treating whole blood, and the operation convenience is improved.

The application discloses a platelet antibody detection and cross matching blocking chromatography kit and a detection method thereof, wherein the kit comprises a U-shaped microwell plate, a chromatography medium for separating platelet immune complexes from non-cell particle components under the action of centrifugal force, freeze-dried platelets, a platelet diluent, a platelet fluorescent staining solution comprising fluoresceinized platelet antibodies specifically labeled for platelets, biotin-labeled anti-human globulin for specifically binding with antibodies bound to the surface of the platelets, avidinized fluorescein for coupling with the biotin-labeled anti-human globulin through a biotin-avidin specific binding system, negative control serum / plasma and positive control serum / plasma. The application combines the blocking chromatography technology with a high-sensitivity flow immunofluorescence method to construct an efficient and accurate platelet antibody detection and cross matching system, which is high in specificity and sensitivity, simple in operation and stable in detection results.

The invention relates to the technical field of medical examination, and provides a detection tube for serum / plasma insufficiency samples, which comprises a blood collection tube, the top of the blood collection tube is fixedly connected with a tube opening convex edge, the top end of the blood collection tube is provided with a detection tube fitting, the detection tube fitting comprises a lower tube and an upper tube, the inner side of the upper tube is provided with a clamping groove in sliding fit with the tube opening convex edge, and the upper tube is provided with a clamping groove. An aluminum film adheres to the top of the upper-section pipe, a liquid pumping hose is fixedly connected to the bottom of the lower-section pipe, a one-way valve is fixedly connected to the liquid pumping hose, and a negative pressure piece which abuts against the pipe opening convex edge to pump out gas in the upper-section pipe to enable the upper-section pipe to generate negative pressure is arranged on the inner side of the clamping groove. A plurality of positioning pieces which are in sliding fit with the outer wall of the convex edge of the pipe orifice are arranged on the outer side of the upper-section pipe and are distributed around the upper-section pipe at equal angles. Through intelligent design and component optimization, the detection feasibility of the serum / plasma insufficiency sample is remarkably improved, and the progress of the medical examination technology is promoted.

This invention provides a material for detecting serum plasma anti-nicotinic acetylcholine receptor antibodies and its method of use. The material comprises HEK293T cells transfected with three recombinant expression plasmids: the first plasmid encodes a truncated AChR α subunit; the second plasmid is a polycistronic plasmid encoding a fusion protein composed of a truncated AChR β subunit, an AChR δ subunit, and rapsyn protein linked by a P2A peptide; and the third plasmid encodes a truncated AChR γ subunit or ε subunit. After co-transfection with PEI, the cells are cultured in fresh complete medium for 25-35 hours after 7-9 hours post-transfection, followed by fixation, blocking, and preservation. This invention, through a three-plasmid system and antigen truncation modification, reduces cytotoxicity while ensuring high expression of the functional pentamer, significantly improving detection sensitivity and reagent shelf life.

The invention discloses application of a reagent for detecting ILA concentration in preparation of a product for predicting esophageal squamous cell carcinoma immunotherapy curative effect, a prediction method and equipment, and relates to the technical field of immunotherapy curative effect prediction. A sample targeted by the reagent for detecting the concentration of indole-3-lactic acid is selected from serum, plasma, blood, tumor tissue or a fecal sample. By establishing the prediction model for the curative effect of the esophageal squamous cell carcinoma immunotherapy, the immunotherapy effect of a patient with the esophageal squamous cell carcinoma can be accurately predicted, and valuable reference bases can be provided for clinicians, so that making of personalized immunotherapy strategies is facilitated, and the effect of the immunotherapy is improved.

An automatic extraction device for large-volume free nucleic acid through a centrifugal column method comprises a back plate, a shifting mechanism and a reagent filling module, the shifting mechanism and the reagent filling module are sequentially and fixedly arranged on the back plate, and a centrifugal column filtering module with a negative-pressure liquid pumping module is arranged at the bottom of the reagent filling module. Through a centrifugal column specifically combined with nucleic acid and a special reagent filling module, after a sample is subjected to cracking and protease K digestion treatment, nucleic acid in the sample is rapidly adsorbed and rapidly washed through a filter membrane, so that protein, pigments, lipids and other impurities are removed to the maximum extent; the obtained total nucleic acid can be stored in an eluent for a long time to be used for a next experiment. The whole device can realize centrifugal column method large-volume free nucleic acid automatic extraction for extracting, enriching and purifying the free total nucleic acid from fresh or frozen serum, plasma, lymph and other cell-free body fluids.

1. Name of the Design Product: Automatic Chemiluminescence Immunoassay Analyzer (AE-200). 2. Use of the Design Product: The product is based on the direct chemiluminescence method of acridinium ester and is used together with detection reagents for qualitative or quantitative detection of analytes in serum, plasma, and urine samples derived from the human body clinically. 3. Design Key Points of the Design Product: Lies in the shape. 4. Picture or Photograph that Best Illustrates the Design Key Points: Front View.

The present invention provides methods for using pre-operative bodily fluid as a source for a tumor reference genome. In some embodiments, the pre-operative bodily fluid is sequenced to identify a genomic variant specific to a tumor. In some embodiments, assays are performed to detect the presence of the genomic variant specific to a tumor identified in the pre-operative bodily fluid in surgical drain fluid. In some embodiments, the bodily fluids may be blood, urine, serum, plasma, saliva, sweat, milk, mucous, semen, vaginal or urethral secretions, cerebrospinal fluid, or surgical lavage fluid.

The invention provides a mental and psychological disorder metabolic index detection kit and application thereof, and belongs to the technical field of biological disease diagnosis. According to the present invention, the sample and the mixed internal standard working solution are mixed, the formic acid acetonitrile solution is added, the centrifugation is performed, and the supernatant is taken, such that the sample pretreatment method can effectively extract a variety of mental and psychological disorder metabolism indexes, and provides the high-resolution, high-specificity and high-sensitivity detection for the liquid chromatography-mass spectrometry method. When the kit and the detection method are used for verifying serum, plasma or urine samples, it is ensured that all parameters meet the requirements, and the test result is good in intra-batch and inter-batch precision and high in accuracy. The kit and the detection method are used for detecting metabolic indexes of mental and psychological disorders in serum, plasma or urine, accurate quantification is provided for clinical projects, and clinical requirements can be met.

The invention discloses a novel amplification-free ultra-sensitive protein detection method and kit based on lanthanide MOF, and belongs to the technical field of protein detection and biosensing. According to the method, the lanthanide MOF material is specifically combined with the charge complementation of the target protein, and is combined with the signal amplification effect of the ssDNA of the labeled fluorophore and phosphate, so that the rapid quantitative detection of the low-abundance protein in the biological sample is realized. The kit comprises a lanthanide MOF material, ssDNA marked with fluorophores, a phosphate buffer solution, a target protein standard substance and the like. An enzyme or nucleic acid amplification step is not needed, the detection limit is as low as 1pg / mL, and compared with an ELISA method, the sensitivity gt is improved; the detection time is shortened to 1-2 h, the detection cost is only 1 / 16 of that of ELISA, and the kit is suitable for detection of protein markers in various biological samples such as serum, plasma and urine and can be widely applied to scenes such as early diagnosis of diseases, precise medical treatment and environmental monitoring.

The present invention discloses an electrochemical aptamer sensor for measuring PD-L1, and its preparation method and application. The sensor is obtained by specifically binding a MWCNTs-PEI-AuNPs modified electrode connected to a PD-L1 aptamer to PD-L1 and COF-AuNPs-PD-L1 antibody-HRP. The sensor can be further prepared into a kit thereof. The above-mentioned sensor and its kit have high detection sensitivity and strong specificity, and are particularly suitable for the detection of PD-L1 in low-limit samples such as serum and plasma. They are convenient and efficient to use. The preparation steps of the above-mentioned detection sensor include: (1) modification of the substrate electrode; (2) connection of the PD-L1 aptamer; (3) blocking nonspecific sites; (4) specific binding to PD-L1: (5) specific binding to COF-AuNPs-PD-L1 antibody-HRP. The preparation method is green and environmentally friendly and easy to scale up.

1. Name of the Design Product: Automatic Chemiluminescence Immunoassay Analyzer. 2. Use of the Design Product: Used for detecting analytes in serum and plasma samples derived from the human body. 3. Design Key Points of the Design Product: Lies in the shape. 4. Picture or Photograph that Best Illustrates the Design Key Points: Perspective view.

The invention discloses a chemiluminescence immunoassay determination kit for detecting colloidal fibrillary acidic protein in a whole blood sample and a preparation method thereof, the determination kit comprises an R1 reagent which is streptavidin-coated magnetic particles, an R3 reagent which is an acridinium ester-labeled GFAP monoclonal antibody, and an R4 reagent which is a biotin-labeled GFAP monoclonal antibody, the reagent R3 and the reagent R4 are dissolved in a diluent, the diluent is a citric acid buffer solution containing a defoaming agent adapted to a whole blood sample system, and the defoaming agent is polydimethylsiloxane. A whole blood sample can be directly detected on a machine after being collected, separation treatment of serum and plasma is not needed, and the problems that in traditional serum and plasma sample detection, sample treatment time is long, and the detection turnover period is long can be effectively solved; meanwhile, the defoaming agent is added to prevent the formation of a bubble-protein compound, so that the detection precision of the reagent is remarkably improved.

The invention relates to the technical field of rapid diagnosis, and particularly discloses an antigen detection test strip and a preparation method thereof. The test strip comprises a bottom plate, and a sample pad, a blank pad, a nitrocellulose membrane and a water absorption pad which are sequentially overlapped on the bottom plate in a chromatography direction, a marking area, a detection line and a quality control line are arranged on the nitrocellulose membrane; the marking area, the detection line and the quality control line are sequentially positioned on the nitrocellulose membrane along the chromatography direction; the detection line is coated with a detection antibody, and the quality control line is coated with a quality control antigen or antibody; an NC membrane treatment component and a quantum dot conjugate are sequentially fixed to the labeling area, the quantum dot conjugate is stacked on the NC membrane treatment component, rapid release of the labeled conjugate can be achieved, detection can be achieved by using a small amount of peripheral blood / vein whole blood / serum / plasma samples, a report can be given within 5 min, and the detection sensitivity is high. The device has the advantages of convenience in use, simplicity in operation and convenience in popularization.

The present application relates to a kind of extraction free DNA reagent based on suction filtration method, kit and extraction method.The kit contains reagent and adsorption column;The reagent includes lysing solution, proteinase K, protease solution, CarrierRNA, binding liquid, washing liquid and eluent;The adsorption column is the silica gel membrane adsorption column that can be used by suction filtration.The present application does not need centrifugal equipment, and the extraction and purification of DNA can be completed by suction filtration, with the characteristics of simple operation, low cost, high extraction rate, low safety risk, suitable for the extraction of free DNA in serum, plasma and other acellular samples.

The present invention provides methods for using pre-operative bodily fluid as a source for a tumor reference genome. In some embodiments, the pre-operative bodily fluid is sequenced to identify a genomic variant specific to a tumor. In some embodiments, assays are performed to detect the presence of the genomic variant specific to a tumor identified in the pre-operative bodily fluid in surgical drain fluid. In some embodiments, the bodily fluids may be blood, urine, serum, plasma, saliva, sweat, milk, mucous, semen, vaginal or urethral secretions, cerebrospinal fluid, or surgical lavage fluid.

The invention discloses a method for high-throughput synchronous analysis of complete O-glycopeptide and N-glycopeptide of immunoglobulin A, and belongs to the technical field of protein analysis. The method comprises the following steps: (1) separating IgA from a sample; (2) preparation and enrichment of IgA glycopeptide; and (3) detecting the IgA glycopeptide by mass spectrometry. According to the method, IgA is separated and purified through electrophoresis, IgA glycopeptides are enriched through a nano material, accurate molecular mass information (observed values) and information provided by a database are obtained through a high-resolution mass spectrum, corresponding possible glycopeptides are speculated, the theoretical molecular weight of the glycopeptides is calculated, and 93 kinds of glycopeptides including N-glycopeptides and O-glycopeptides are totally identified. According to the method, complete N glycopeptides and O glycopeptides of IgA in serum / plasma and other IgA-containing body fluid samples can be simultaneously determined, and information of glycoforms and glycosylation sites on the glycopeptides is reserved. The method has the advantages of strong operability, high sensitivity, good accuracy and good stability.